Suppr超能文献

DCLK1-异构体 2 选择性剪接变体促进胰腺肿瘤免疫抑制 M2-巨噬细胞极化。

DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization.

机构信息

Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

OU Cancer Institute, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

出版信息

Mol Cancer Ther. 2020 Jul;19(7):1539-1549. doi: 10.1158/1535-7163.MCT-19-0776. Epub 2020 May 5.

Abstract

Tumor-associated M2-macrophages are one of the most abundant immunosuppressive cell types in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME). However, the molecular mechanisms responsible for the generation of M2-macrophages are unclear. Here, we demonstrated that overexpression of DCLK1-isoform2 in AsPC1 and MIA PaCa2 cells resulted in the polarization of M1-macrophages toward an M2 phenotype via secreted chemokines/cytokines. These M2-macrophages enhanced parental PDAC cell migration, invasion, and self-renewal, and this was associated with increased expression of Snail and Slug. We observed distinct expression of Dclk-isoform2, marked infiltration of M2-macrophages, and a marginal increase of CD8 T cells in 20-week-old KPCY mice pancreas compared with 5 weeks old. Utilizing an autochthonous mouse model of pancreatic adenocarcinoma, we observed distinct immunoreactive Dclk1 and arginase1 in tissues where CD8 T-cell infiltration was low and observed a paucity of DCLK1 and arginase1 staining where CD8 T-cell infiltration was high. Finally, we found that DCLK1-isoform2 tumor-educated M2-macrophages inhibit CD8 T-cell proliferation and granzyme-B activation. Inhibition of DCLK1 in an organoid coculture system enhanced CD8 T-cell activation and associated organoid death. We conclude that DCLK1-isoform2 is a novel initiator of alternate macrophage activation that contributes to the immunosuppression observed in the PDAC TME. These data suggest that tumor DCLK1-isoform2 may be an attractive target for PDAC therapy, either alone or in conjunction with immunotherapeutic strategies.

摘要

肿瘤相关的 M2 型巨噬细胞是胰腺导管腺癌 (PDAC) 肿瘤微环境 (TME) 中最丰富的免疫抑制细胞类型之一。然而,负责生成 M2 型巨噬细胞的分子机制尚不清楚。在这里,我们证明在 AsPC1 和 MIA PaCa2 细胞中过表达 DCLK1-isoform2 会通过分泌趋化因子/细胞因子导致 M1 型巨噬细胞向 M2 表型极化。这些 M2 型巨噬细胞增强了亲本 PDAC 细胞的迁移、侵袭和自我更新能力,这与 Snail 和 Slug 的表达增加有关。与 5 周龄相比,在 20 周龄的 KPCY 小鼠胰腺中,我们观察到 Dclk-isoform2 的明显表达、M2 型巨噬细胞的显著浸润以及 CD8 T 细胞的少量增加。利用胰腺腺癌的自发小鼠模型,我们观察到在 CD8 T 细胞浸润低的组织中存在明显的免疫反应性 Dclk1 和精氨酸酶 1,而在 CD8 T 细胞浸润高的组织中则观察到 DCLK1 和精氨酸酶 1 染色不足。最后,我们发现 DCLK1-isoform2 肿瘤诱导的 M2 型巨噬细胞抑制 CD8 T 细胞的增殖和颗粒酶-B 的激活。在类器官共培养系统中抑制 DCLK1 可增强 CD8 T 细胞的激活及其相关类器官的死亡。我们得出结论,DCLK1-isoform2 是一种新的替代巨噬细胞激活的启动子,有助于 PDAC TME 中观察到的免疫抑制。这些数据表明,肿瘤 DCLK1-isoform2 可能是 PDAC 治疗的一个有吸引力的靶点,无论是单独使用还是与免疫治疗策略联合使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16a8/7883901/ddedee5c7d4d/nihms-1669032-f0001.jpg

相似文献

10
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.巨噬细胞PI3Kγ驱动胰腺导管腺癌进展。
Cancer Discov. 2016 Aug;6(8):870-85. doi: 10.1158/2159-8290.CD-15-1346. Epub 2016 May 13.

引用本文的文献

7
Regulatory mechanism of macrophage polarization based on Hippo pathway.基于 Hippo 通路的巨噬细胞极化调控机制。
Front Immunol. 2023 Nov 28;14:1279591. doi: 10.3389/fimmu.2023.1279591. eCollection 2023.

本文引用的文献

2
Regulation of immune responses by tuft cells.被毛细胞调节免疫反应。
Nat Rev Immunol. 2019 Sep;19(9):584-593. doi: 10.1038/s41577-019-0176-x.
4
Targeting Tumor-Associated Macrophages in Cancer.靶向肿瘤相关巨噬细胞治疗癌症。
Trends Immunol. 2019 Apr;40(4):310-327. doi: 10.1016/j.it.2019.02.003. Epub 2019 Mar 17.
6
Organoid Modeling of the Tumor Immune Microenvironment.类器官肿瘤免疫微环境模型构建
Cell. 2018 Dec 13;175(7):1972-1988.e16. doi: 10.1016/j.cell.2018.11.021.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验